Activiomics has developed a groundbreaking and patented technology that will enable a transformation in the way in which biomarkers are identified, diagnostics are developed and drug candidates are identified and profiled.
Activiomics' technology centres around novel mass spectrometry based approaches for the global quantitative analysis of phosphorylation sites. Activiomics' TIQUAS (Targeted In-depth QUAntification of cell Signalling) technology enables the quantification of thousands of phosphorylation events from a given tissue sample and the subsequent markers of response that are identified will enable the development of future diagnostics.
|
As at 31 Dec 2012 |
IP Group holding |
IP Venture Fund* holding |
48.6% |
13.8% |
|
*IP Group has a 10%
economic interest in IP
Venture Fund |
Holdings represent undiluted beneficial equity interest excluding debt